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What’s already known about this topic? 1 
• Oral propranolol is widely prescribed as first line treatment for 2 
complicated infantile haemangiomas. 3 
• Anecdotally, prescribing practice differs widely, but no international 4 
survey has been undertaken to date.   5 
 6 
What does this study add? 7 
• This is the first European study of current practice in the use of oral 8 
propranolol in infantile haemangiomas, based on the largest case 9 
series of its kind. 10 
• The PITCH survey confirms the overall efficacy and safety of 11 
propranolol, with the majority of paediatric dermatologists using 12 
2mg/kg/day as therapeutic dose.  13 
• Any future clinical trial should therefore include a 2mg/kg/day treatment 14 
arm.15 
5 
 
Abstract  1 
 2 
Background: Oral propranolol is widely prescribed as first line treatment for 3 
infantile haemangiomas (IHs) and anecdotally prescribing practice differs 4 
widely between centres. 5 
Objectives: The Propranolol In the Treatment of Complicated 6 
Haemangiomas (PITCH) Taskforce was founded to establish patterns of use 7 
of propranolol in IHs. 8 
Methods: Participating centres entered data on all of their patients who had 9 
completed treatment with oral propranolol for IHs, using an online data 10 
capture tool. 11 
Results: The study cohort comprised 1096 children from 39 centres in eight 12 
European countries. 76.1% were female and 92.8% had a focal IH, with the 13 
remainder showing a segmental, multifocal or indeterminate pattern. The main 14 
indications for treatment were periocular location (29.3%), risk of cosmetic 15 
disfigurement (21.1%), and ulceration and bleeding (20.6%).  69.2% of 16 
patients were titrated up to a maintenance regimen, which consisted of 17 
2mg/kg/day (85.8%) in the majority of cases. 91.4% of patients had an 18 
excellent or good response to treatment.  Rebound growth occurred in 14.1% 19 
upon stopping, of which 53.9% were restarted and treatment response was 20 
recaptured in 91.6% of cases. While there was no significant difference in the 21 
treatment reponse, comparing a maintenance dose of <2mg/kg/day versus 22 
2mg/kg/day versus >2mg/kg/day, the risk of adverse events was significantly 23 
higher (OR=1 vs adjusted OR=0.70 (0.33-1.50), p=0.36 vs 2.38 (1.04-5.46), 24 
p=0.04, ptrend<0.001). 25 
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Conclusions: The PITCH survey summarises the use of oral propranolol 1 
across 39 European centres, in a variety of IH phases and could be used to 2 
inform treatment guidelines and the design of an intervention study.3 
7 
 
Introduction 1 
Haemangiomas are the commonest benign tumour of infancy, with a postnatal 2 
incidence of around 5%.1 In the latest International Society for the Study of 3 
Vascular Anomalies classification, infantile haemangiomas (IHs) are 4 
morphologically subdivided into focal or localised, segmental, indeterminate 5 
and multifocal IHs.2 They typically develop during the first month after birth 6 
and follow a characteristic evolution from early rapid proliferation to a 7 
stabilisation and a slow involution phase, which often takes years. Around 8 
20% of IHs need medical attention due to complications, for instance 9 
bleeding, ulceration or threat to vision.3 Since the serendipitous discovery of 10 
the benefit of propranolol in IHs in 20084, it has been rapidly adopted as a first 11 
line treatment for complicated lesions, replacing oral cortciosteroids. In 12 
addition to numerous case series and case reports, three randomised 13 
controlled trials have investigated the efficacy of propranolol in IHs, with the 14 
largest trial (n=456) comparing a dose of 3mg/kg/day with 1mg/kg/day dose 15 
and placebo, which found that the higher dose was significantly superior with 16 
regard to treatment efficacy.5,6,7 However, this study only used propranolol for 17 
a maximum of 24 weeks, excluded patients outside the proliferation phase as 18 
well as children with life- or function-threatening or severely ulcerated IHs for 19 
ethical reasons, owing to the inclusion of a placebo group.5 This would, for 20 
instance, have excluded segmental IH (SIHs). 2mg/kg/day is the most 21 
commonly reported dose in the literature and between-centre heterogeneity in 22 
the use of oral propranolol in complicated IHs is likely, although no survey of 23 
clinical practice has so far been conducted across the European paediatric 24 
dermatology community to confirm this impression.8,9 25 
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We therefore founded the Propranolol In the Treatment of Complicated 1 
Haemangiomas (PITCH) Taskforce in 2013 with three main objectives: i) to 2 
ascertain patterns of propranolol prescribing in Europe, ii) to collect data on 3 
the safety and efficacy of oral propranolol, and iii) to help inform the 4 
formulation of treatment guidelines as well as the design of future intervention 5 
studies. 6 
7 
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Patients and Methods 1 
Study data on patients who had treatment of an IH with oral propranolol were 2 
collected across eight European countries (Denmark, Germany, Ireland, Italy, 3 
the Netherlands, Spain, Sweden, and the UK), using the REDCap (Research 4 
Electronic Data Capture) electronic database tool (Vanderbilt University, 5 
Nashville, Tennessee, USA).10 The study was conceived and coordinated by 6 
the Paediatric Dermatology Department at St John’s Institute of Dermatology, 7 
Guy’s and St Thomas’ Hospital NHS Foundation Trust, London, UK, and 8 
approved by the Research and Development Department at Guy’s and St 9 
Thomas’ Hospital NHS Foundation Trust. 10 
Data were collected between June 2013 and November 2014. In the UK, 11 
invitations to participate were disseminated through the British Society for 12 
Paediatric Dermatology (BSPD) membership list. Paediatric Dermatology 13 
centres from seven other European countries were also invited to take part. 14 
Centres were asked to only enter patients who had completed propranolol 15 
therapy for an IH. The following data were collected: country of practice, 16 
speciality, patient sex, subtype of IH (focal, segmental or other type, including 17 
multifocal IHs), treatment indication (periocular with threat to vision, nasal tip, 18 
causing functional disturbance, ulceration, recurrent bleeding, uncomplicated 19 
IH on the face other than periocular or nasal tip, parental request, and other 20 
indication), age at treatment commencement, adjunctive therapies, pre-21 
initiation screening investigations, treatment dosage and duration, adverse 22 
events, treatment response (from ‘excellent/complete response’, ‘good’, ‘poor’ 23 
to ‘none’), rebound growth, and re-treatment with propranolol. 24 
10 
 
Where individual patient data was incompletely entered, we contacted the 1 
study centres to collect missing information.  2 
We present primarily descriptive analyses. Age at treatment commencement, 3 
duration of treatment, and the age therapy was stopped are presented as 4 
medians and ranges due to the non-normal distribution of the data. Odds 5 
ratios and corresponding 95% confidence intervals were calculated in relation 6 
to treatment response and risk of rebound growth. Following univariate 7 
analysis, significant risk estimates were mutually adjusted in logistic 8 
regression. The following variables were evaluated as potential confounders: 9 
gender, the age treatment was started, the length of treatment, the age 10 
treatment was stopped, and the type of IH. The statistical analyses were 11 
conducted by CF and EW, using SPSS software (Sun Microsystems Inc.) 12 
version 19.0. We followed the STROBE guidelines for the reporting of 13 
observational studies throughout.14 
11 
 
Results 1 
Data from 1096 patients were entered from 39 individual centres in 8 2 
European countries (Denmark (n=35 patients), Germany (193), Ireland (136), 3 
Italy (65), the Netherlands (23), Spain (92), Sweden (72), UK (481)). 4 
 5 
Patient demographics and clinical features 6 
The majority (92.8%; 1018) of patients had focal IHs and were female 7 
(76.1%). The median age at initiation of propranolol was 17 weeks (range 0.5-8 
396). 19.8% (217) of the total cohort were premature (defined as born at <37 9 
weeks of gestation). 5.5% (60) had a SIH, 0.8% (9) multifocal IHs. Local 10 
investigators also entered data on 10 children treated with propranolol for a 11 
congenital haemangioma, but these cases were not included in the efficacy-12 
related analyses as they are distinctly different from IHs. Of the focal IHs, 13 
77.2% (786) were treatment initiated in the rapid growth phase, 21.5% (219) 14 
during stabilisation and 1.3% (13) in the involution phase. The three main 15 
indications for treatment were ‘periocular location with threat to vision’ (29.3%; 16 
321), ‘risk of cosmetic disfigurement on the face’ (21.1%; 232) and ‘ulceration 17 
and bleeding’ (20.6%; 226). The other indications are displayed in Fig. 1. At 18 
the time of initiation, 87.0% (954) were on no adjunctive treatment, while 6.1% 19 
(67) were taking oral glucocorticoids, 2.3% (25) were also undergoing laser 20 
therapy, 2.0% (22) were on topical glucocorticoids, and 2.6% (29) were on 21 
‘other’ therapies, including topical timolol. 22 
 23 
Pre-initiation screening 24 
12 
 
69.1% (757) of patients had blood tests before starting propranolol, of whom 1 
93.5% (708) had a glucose level, 88.8% (672) a full blood count, 86.0% (651) 2 
a renal profile, 82.0% (621) liver function tests, and 61.8% (468) a thyroid 3 
profile. 92.3% (1013) underwent a cardiological or radiological investigation 4 
before starting propranolol. 88.5% (971) underwent an electrocardiogram 5 
(ECG), 67.5% (741) had an echocardiogram (ECHO), 7.7% (84) magnetic 6 
resonance imaging (MRI), and 15.7% (172) an abdominal ultrasound. 98.4% 7 
of patients underwent a full clinical examination, before treatment was started. 8 
54.9% (602) had a specialist cardiology evaluation, and 50.4% (553) were 9 
also assessed by a general paediatrician. 10 
 11 
Treatment initiation and dosage regimens 12 
89.8% (985) of patients had propranolol initiated in a hospital setting; 44.2% 13 
(435) as day cases, 26.4% (260) had an overnight stay, and 29.4% (290) had 14 
a hospital stay of two or more nights. The most common investigations 15 
undertaken during initiation were heart rate (98.3%, 968) and blood pressure 16 
monitoring (98.9%, 974), with 54.0% (532) also having glucose and 32.6% 17 
(321) ECG monitoring. 69.2% (759) of patients were started on a lower 18 
dosage and subsequently had dose incrementation to a maintenance 19 
regimen. The most frequent initiation dosage was 1mg/kg (47.1%, 517). 20 
18.6% (204) of patients were started at <1mg/kg/day and 26.2% (288) at 21 
2mg/kg/day. The majority of patients had a daily maintenance dose of 22 
2mg/kg/day (85.8%, 939). Only 4.8% (52) of the cohort had a daily 23 
maintenance dosage of <2mg/kg. 11.0% (103) had a dosage of >2mg/kg. 24 
Most children were started on treatment during the rapid growth phase 25 
13 
 
(71.6%, 785), but in a significant number treatment was initiated in the 1 
stabilisation (20.0%, 219) and a few even during the involution phase because 2 
of ulceration (1.2%, 13). 3 
 4 
Treatment response and rebound growth 5 
The median length of treatment was 32 weeks (range 2-184). 19.8% (215) of 6 
patients were reported to have an excellent response compared to 72.0% 7 
(782) with a good and 7.0% (76) with a poor or no response seen in 1.2% 8 
(13). There was a trend for a higher ‘good or excellent’ (vs ‘poor or no’) 9 
treatment response in the 2mg/kg/day (adj OR=1.25, 0.43-3.62, p=0.68) and 10 
the above 2mg/kg/day dose groups (adj OR=1.74, 0.45-6.57, p=0.42) but the 11 
results were statistically not significant, and there was no association with 12 
duration of treatment. 13 
With regard to the phase of the IH when treatment was initiated, our results 14 
suggest that there is still benefit from treating patients in the stabilisation 15 
phase, although the response rate was lower than in the rapid growth phase, 16 
with 18.3% of patients having a poor or no response compared to 5.6% of 17 
patients in the rapid growth phase. 18 
Most patients (76.8%, 842) had their dose of propranolol titrated down before 19 
stopping. The median age at stopping was 56 weeks (range 4-412).  20 
14.1% (154) of patients were reported to experience rebound growth of the IH 21 
after stopping treatment. Of those experiencing rebound growth, 53.9% (83) 22 
were restarted on propranolol, representing 7.6% of the total cohort. On 23 
retreatment, response was recaptured in the vast majority (91.6%). 24 
 25 
14 
 
Predictors of rebound growth 1 
Although the median age when treatment was stopped was lower (52 weeks, 2 
interquartile range (IQR) 40-64) in the rebound growth group compared to 56 3 
weeks (IQR 42-72) in the non-rebound growth group, this difference was not 4 
statistically significant (p=0.08, Table 1). The rebound growth risk reduction 5 
was most noticeable in the children who were 70 weeks or older when 6 
treatment was stopped (OR=0.58, 95% CI 0.34-0.99, p=0.048), compared to 7 
children in the other age quartiles: up to 40 weeks (OR=1, reference group), 8 
40-54 weeks (OR=0.83, 0.50-1.37, p=0.46), and 54-70 weeks (OR=0.90, 9 
0.55-1.48, p=0.68; ptrend<0.001). However, the results became non-significant 10 
for children aged 70 weeks and above, when age at treatment initiation and 11 
treatment length were taken into account in multivariate logistic regression 12 
analysis. The results also did not appreciably change when the analyses were 13 
restricted only to children with focal IH or IHs in the rapid growth phase. 14 
 15 
Segmental infantile haemangiomas 16 
Our cohort included 60 SIHs. 35.0% (21) had an associated abnormality with 17 
cerebral artery malformations, consistent with a diagnosis of PHACE 18 
syndrome, being the commonest (15.0%, 9). Other associations are shown in 19 
Table 2. The median length of treatment for SIHs was 45 weeks (range 8-20 
139). 31.7% (19) patients showed rebound growth, compared to 13.1% for 21 
focal IHs (adjusted OR=3.33, 1.85-6.01, p<0.001). 16.7% (10) of patients 22 
were restarted on propranolol, and all of these recaptured their original 23 
treatment response. 24 
 25 
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Adverse events 1 
19.6% (215) of the cohort experienced an adverse event, and these are 2 
shown in Table 1. Of those experiencing side effects, 55.3% (119) continued 3 
with propranolol with the dose unchanged. 25.1% (54) had a dose adjustment, 4 
and treatment was stopped in 19.5% (42) of cases who experienced side 5 
effects, which represented 3.8% of the PITCH cohort. The reasons for 6 
treatment cessation were: wheezing (15), sleep disturbance (8), diarrhoea (5), 7 
significant hypoglycaemia (4), worsening of the ulceration (4), persistent 8 
cough (2), irritability and poor feeding (1), concern about delayed 9 
development (1), and one episode of cyanosis. 10 
The risk of experiencing an adverse event was more than twice as high in 11 
children on a maintenance dose of over 2mg/kg/day compared to children on 12 
a lower treatment dose: adj OR <2mg/kg/day = 1, adj OR 2mg/kg/day = 0.70 13 
(0.33-1.50), p=0.36 vs adj OR >2mg/kg/day = 2.38 (1.04-5.46), p=0.04 (p 14 
trend<0.001), although no individual category of adverse events made a 15 
significant standalone contribution to this risk increase. In addition, there was 16 
a more than 50% lower rate of adverse events in the children who had their 17 
dose incremented compared to those who were started directly on the 18 
therapeutic dose (adj OR = 0.48 (0.35-0.65), p<0.001). 19 
 20 
Adverse events among children without baseline investigations 21 
The necessity and depth of pre-initiation screening is an area of uncertainty, 22 
and we therefore examined the adverse events and resultant changes in 23 
propranolol dosages during treatment in patients with pre-initiation screening 24 
and those without. The relative adverse events in the groups with/without 25 
16 
 
ECGs and ECHOs prior to commencement were non-significant and are 1 
summarised in Table 4. Similarly, there was no significant difference in the 2 
frequency of other, non-cardiovascular side effects, such as hypoglycaemia, 3 
cold peripheries, sleep disturbance, diarrhoea, and wheezing. 4 
5 
17 
 
Discussion 1 
The PITCH survey confirms the efficacy and safety of propranolol therapy in 2 
IHs, with a good or excellent response seen in over 90% of patients. Although 3 
there was a trend towards higher efficacy across the dose ranges, the 4 
difference between the proportion of good/excellent responses in the 5 
2mg/kg/day and the above 2mg/kg/day dose groups was statistically not 6 
significant, whereas the risk of adverse events was significantly higher. 7 
The PITCH Taskforce survey is the first international survey of its kind, 8 
collecting data from eight European countries and to the best of our 9 
knowledge represents the largest single case series of children with 10 
complicated IHs treated with oral propranolol, although a previous systematic 11 
review collected data from 1,264 patients included in 41 individual studies.11 12 
Limitations of our survey include the retrospective nature of data collection, 13 
which has an inherent risk of reporting bias. Although we strongly encouraged 14 
individual study centres to enter all their patients who completed oral 15 
propranolol for a IH, there might have been patients with incomplete clinical 16 
records and that study centres therefore decided not to enter these patients 17 
into the study. It is also possible that the threshold of oral propranolol 18 
treatment for IHs changed over the years, as our experience and the 19 
published evidence of its efficacy increased. This would have biased the early 20 
cases towards greater severity. 21 
In addition, the classication of IHs is not straightforward, and this might have 22 
resulted in misclassification of some segmental and indeterminate IHs in 23 
particular. We also had no information on depth and size of the IH and side 24 
effects were reported by physicians, not parents, which could have led to 25 
18 
 
reporting bias. We were also not able to use more objective outcome 1 
measures, and there are no long-term follow up data available on this cohort. 2 
Another limitation of our survey is that we only included patients who were 3 
treated with propranolol. We are therefore not able to say how many patients 4 
were not started on oral propranolol because of abnormal baseline 5 
investigations. However, the rate of side effects in those who had no baseline 6 
investigations was comparable to those who had tests done prior to starting 7 
oral propranolol. 8 
The strongest evidence for the efficacy of oral propranolol in IH so far comes 9 
from a recently published randomised controlled trial that compared a dose of 10 
1mg/kg/day with 3mg/kg/day, showing clear superiority of the higher dose in 11 
treatment efficacy.2  However, we found no difference between 3mg/kg/day 12 
and the much more commonly used dose of 2mg/kg/day. Our results also 13 
suggest that IHs can benefit from oral propranolol treatment even during the 14 
stabilisation phase, in line with other, smaller studies.12,13  Furthermore, 15 
ulcerated lesions are often refractory to a number of older treatment 16 
modalities14 but may often respond well to propranolol, with 91.6% of IHs 17 
treated for ulceration/bleeding having a ‘good or excellent’ response. This 18 
high response rate is in keeping with other published evidence.15 19 
As for potential side effects, the PITCH survey suggests that treatment with 20 
propranolol is safe. Most reported side effects were mild with the most 21 
common side effects being sleep disturbance and cold peripheries, 22 
accounting for 54% of all adverse events. 3.8% of our cohort ceased 23 
treatment due to side effects. Hypoglycaemia was reported  in only 0.7%, 24 
presumably because parents are advised to withhold propranolol at times of 25 
19 
 
reduced oral intake.16,17  Whilst adverse events were generally mild, little is 1 
known about potential longer term side effects.  Propranolol is well known to 2 
cross the blood brain barrier and concerns have been raised over the drug’s 3 
potential to lead to neurodevelopmental delay, and further research and long-4 
term follow up is required.18  5 
In our cohort, there was a clear association between the frequency of adverse 6 
events and the treatment dose with twice the number of adverse events seen 7 
in the 3mg/kg/day group compared to those receiving 2mg/kg/day or lower 8 
doses. Given the lack of significant difference in efficacy between these two 9 
doses, it seems prudent to use the lower dose, as long as the observed 10 
treatment effect is adequate. In addition, there was a more than 50% lower 11 
rate of adverse events in the children who had their dose incremented 12 
compared to those who were started directly on the therapeutic dose (adj OR 13 
= 0.48 (0.35-0.65), p<0.001), and dose up titration has indeed been 14 
recommended in current treatment guidelines.18 15 
The need for in-depth investigations prior to commencement of propranolol 16 
remains another area of debate, and our data support a rationalisation of pre-17 
treatment screening, in keeping with a recent European expert consensus 18 
statement.19 While initial recommendations suggested the need for full 19 
cardiological investigations with ECGs and ECHOs,20 current US and 20 
European consensus guidelines state that full clinical examination and an 21 
ECG are sufficient.18,21  Since we did not find a significant difference between 22 
rates of adverse events in those patients with pretreatment ECHOs and ECGs 23 
versus those that started without, apart from a slightly higher rate of 24 
bradycardia in those patients who did not undergo a pretreatment ECG (1.6% 25 
20 
 
vs 0.4% p=0.09), we feel the additional value of an ECG, in the face of an 1 
unremarkable history and physical examination including auscultation, 2 
remains uncertain.22 3 
With 60 cases, the PITCH survey assembled the to largest case series of 4 
SIHs to date, 15% of whom had underlying cerebral vascular anomalies. 5 
There were similar rates of adverse events in this group, when compared to 6 
the general cohort. 18.3% of patients with SIHs experienced side effects, but 7 
in only 1.7% of cases did this lead to cessation of treatment. No 8 
cerebrovascular events were reported, and the efficacy and safety in this 9 
group were overall comparable to the rest of the cohort, although the risk of 10 
rebound growth was double that of the rest of the cohort, potentially due to the 11 
increased depth of these lesions. 12 
Rebound growth was seen in 14.1% of the PITCH cohort. Those who were 17 13 
months or older when treatment was stopped had a significantly lower risk of 14 
rebound growth in univariate analysis, but this effect was lost in multivariate 15 
regression analysis. Interestingly, when we stratified rebound growth rates by 16 
daily dosage, we found higher rates of rebound growth in the group treated 17 
with 3mg/kg/day (27.5% vs 13.0% at 2mgkg and 16.0% at <2mg/kg). Our 18 
results may be explained by the type or size of IHs which necessitated a 19 
higher treatment dose. As for rebound growth rates, other studies found these 20 
to be between 5% and over 25%.3,23,24,25,26,27 Previous predictors of rebound 21 
growth after cessation of propranolol have included size and depth of IHs, 22 
SIHs27 were all variables we were not able to examine in this cohort.28 23 
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In summary, oral propranolol has emerged as the first line treatment for 1 
complicated IHs. Our large cohort study confirms that it can be used 2 
effectively and safely across a range of indications and phases of IH growth.  3 
Rebound growth is a significant risk, particularly in SIHs. However, we did not 4 
find that using propranolol at 3mg/kg/day reduced this risk significantly. As we 5 
found good efficacy across a range of dosages (1-3mg/kg) with no significant 6 
difference in efficacy between 2mg/kg/day and 3mg/kg/day, the optimum 7 
treatment dose remains under discussion, also because the rate of side 8 
effects appeared higher in children treated with 3mg/kg/day. An adequately 9 
powered randomised controlled trial comparing 2mg/kg/day with 3mg/kg/day 10 
is therefore required.11 
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Figure 1. Indications for treatment with oral propranolol1 
24 
 
Table 1. Predictors of rebound growth 1 
 2 
 Rebound growth No rebound 
growth 
 
Characteristic Median weeks 
(IQR) 
N=154 
Median weeks 
(IQR) 
N=942 
 
P value 
Age at treatment 
initiation 
 
16 (9-28) 17 (12-28) 0.45 
Age when treatment 
stopped 
52 (40-64) 56 (42-72) 0.08 
Length of treatment 32 (24-48) 32 (24-48) 0.12 
 3 
IQR – interquartile range 4 
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Table 2. Structural abnormalities associated with segmental infantile 1 
haemangiomas 2 
Structural abnormalities associated with 
segmental infantile haemangiomas 
% (n) of segmental infantile 
haemangiomas (total n=60) 
Cerebral artery anomalies 15.0% (9) 
Posterior fossa abnormalities  6.7% (4) 
Ventricular septal defect 5.0% (3) 
Patent foramen ovale 5.0% (3) 
Atrial septal defect 5.0% (3) 
Sternal cleft/supraumbilical raphe 5.0% (3) 
Coarctation of the aorta 3.3% (2) 
Patent ductus arteriosus 1.7% (1) 
Intracranial haemangioma 1.7% (1) 
 3 
4 
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 1 
Table 3: Adverse events experienced whilst on oral propranolol treatment 2 
Adverse event % of total cohort (n) 
Sleep disturbance 8.2% (90) 
Cold peripheries 4.6% (51) 
Wheezing 2.8% (31) 
Diarrhoea 1.9% (21) 
Symptomatic hypotension 1.6% (18) 
Symptomatic hypoglycaemia 0.7% (8) 
Symptomatic bradycardia 0.5% (6) 
Other 3.3% (36) 
 3 
4 
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Table 4. Adverse event frequency and resulting dose adjustments in those with/without pre-1 
initation ECGs and ECHOs 2 
 ECHO  
Yes 
ECHO  
No 
p ECG 
Yes 
ECG 
No 
p 
Total 
numbers (%) 
741 (67.5) 356 (32.5) - 971 (88.5) 126 (11.5) - 
Adverse  
events (total) 
20.0% (148) 18.9% (67) 0.67 19.2%(186) 23.0%(29) 0.28 
Hypotension 1.8% (13) 1.4% (5) 0.67 1.5% (15) 2.4% (3) 0.48 
Bradycardia 0.5% (4) 0.6% (2) 0.96 0.4% (4) 1.6% (2) 0.09 
 3 
ECG – electrocardiogram, ECHO - echocardiogram4 
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